June 8, 2026 - 10:49

Genworth Financial continues to lean heavily on its majority stake in Enact Holdings, a mortgage insurance provider that now stands as the company's most valuable asset. With Enact currently valued at roughly $4.7 billion, Genworth's own market capitalization remains surprisingly low in comparison. This disconnect suggests that the broader market has not fully priced in the worth of Genworth's core holding.
Analysts point out that Genworth's stock trades at a significant discount to the implied value of its Enact shares alone. If you strip out the value of the Enact stake, the rest of Genworth's business -- including its legacy life insurance and long-term care operations -- appears to be valued at a fraction of what it might be worth. This creates a compelling opportunity for investors who see the gap narrowing over time.
The company has also made progress in managing its older insurance liabilities, which have long been a drag on its balance sheet. While those legacy risks are not gone, they are better contained than in previous years. As Enact continues to generate steady profits, Genworth is in a stronger position to address its remaining obligations.
For now, the stock remains a buy for those willing to bet that the market will eventually recognize the true value of the Enact holding. The discount is wide, but the driver is clear.
November 11, 2026 - 03:35
Resideo Reports Third Quarter 2026 Financial Performance and Outlook UpdateResideo Technologies, Inc. has shared its financial results for the third quarter of 2026, which concluded on October 3. The company, known for its innovative control and sensing solutions in the...
November 10, 2026 - 13:34
Hong Kong's Financial Transformation: China Aims for Global InfluenceA recent report explores how Beijing is reshaping Hong Kong into a key player in the global financial landscape. The analysis, conducted by ASPI`s Center for China Analysis and Enodo Economics,...
November 10, 2026 - 09:52
BitGo Holdings Reports Significant Revenue Decline in Q3BitGo Holdings, known by the ticker BTGO, has revealed a troubling 50.9% drop in year-over-year revenue for the third quarter. The decline is largely attributed to a slowdown in digital asset...
November 9, 2026 - 21:06
New Drug Application Submitted for Azetukalner in Focal SeizuresIn September 2026, a New Drug Application for azetukalner, a treatment for focal seizures, was submitted to the U.S. Food and Drug Administration. This marks a significant step forward in expanding...